Serving as an adjunct to insulin, the double-acting inhibitor of SGLT1 and SGLT2, sotagliflozin can enhance the manage of blood glucose levels in patients diagnosed with type 1 diabetes. Here, INS is linked to type 1 diabetes mellitus.